Stryker Corp

Stryker maintains a capital structure characterized by significant leverage, with long-term debt of $14.86 billion against total equity of $22.42 billion, resulting in a debt-to-equity ratio of 0.66. The company holds $4.01 billion in cash and equivalents, leading to a negative net cash position after subtracting total debt, which contributes to a medium liquidity risk assessment. The current ratio is not explicitly provided, but the balance sheet shows total liabilities of $25.42 billion versus total assets of $47.84 billion. Operating cash flow stands at $5.04 billion, which comfortably covers capital expenditures of $761 million, indicating strong internal cash generation despite the debt load.

Profitability metrics show a gross profit of $16.07 billion on revenue of $25.12 billion, implying a gross margin of approximately 64%. Operating income is $4.89 billion, and net income is $3.25 billion. The return on equity is 14.48%, and the return on assets is 6.78%. These returns are generated on a market capitalization of $119.88 billion, with a price-to-earnings ratio of 36.93 and an EV/EBITDA of 26.74. The price-to-book ratio is 5.35. Without specific cohort median data provided in the input, these ratios are evaluated in isolation, though the high P/E suggests the market prices in significant future growth or stability.

Revenue concentration by segment or geography is not detailed in the provided data. The company operates globally, but specific regional breakdowns or segment revenue mixes are absent from the current snapshot. Therefore, no specific claims can be made regarding geographic exposure or segment dependency based on the available information.

Growth trajectory analysis is limited by the absence of historical period data in the input. The current revenue figure of $25.12 billion represents the latest normalized period, but without prior year or quarterly comparisons, year-over-year growth rates cannot be calculated. The company’s ability to sustain growth is implied by the high valuation multiples, but specific historical trends are not available for review.

Risk factors include a medium liquidity risk and low dilution risk. The key flag notes that net cash is negative after subtracting total debt, which is a standard characteristic for mature, acquisition-driven medical device companies but requires monitoring of interest coverage and refinancing needs. The dilution risk is assessed as low, with basic and diluted shares outstanding both at 386.5 million, indicating minimal impact from stock-based compensation or other dilutive instruments in the current period.

Recent events and analyst sentiment are positive, with a mean price target of $387.46 and a median target of $385.00, compared to the current market price of $310.18. The mean recommendation is 1.80, with 12 strong buys and 12 buys, suggesting strong institutional confidence. The high price target of $465.00 and low of $315.00 indicate a wide range of expectations, but the consensus leans heavily toward upside potential.

Stryker Corp (SYK.O) experienced a significant shift in its shareholder base, marked by a major modification in holdings by investor ID 931. This investor dramatically increased their position from 2,585 shares, valued at approximately $0.85 million, to 134,085 shares, worth roughly $43.9 million. This substantial accumulation, detected on June 23, 2026, represents a jump in portfolio weight from 0.0004% to 0.021% as of March 31, 2026. The magnitude of this change is notable given that it constitutes the first analysis for this ticker, meaning there is no prior basis for computing historical deltas. The investor’s move to acquire over 131,000 additional shares signals a strong conviction in the company’s prospects, transforming a negligible stake into a more meaningful holding within a short timeframe. This activity occurs within a broader context where Stryker Corp is tracked by 37 top holders and maintains membership in one major index. While the company currently has one reported officer and no analyst coverage in this dataset, the presence of 37 top holders suggests a diversified institutional interest that may be influenced by such significant individual moves. The significance of this holder change lies in its potential to influence market perception and liquidity dynamics for SYK.O. As a major severity event, the rapid expansion of investor ID 931’s stake highlights active engagement from key market participants, warranting close attention from other stakeholders monitoring the company’s ownership structure and potential future trading activity.